160 related articles for article (PubMed ID: 35642346)
1. TOX Outperforms FOXP3, CD4 and GATA3 in Histopathological Diagnosis of Early Mycosis Fungoides.
Ahmed MM; Hegazy AA; Embaby A; Nawwar EM; Hegazy SA; Ibrahim HM; Gobran MA
Turk Patoloji Derg; 2023; 39(1):15-22. PubMed ID: 35642346
[TBL] [Abstract][Full Text] [Related]
2. Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.
Mehdi SJ; Moerman-Herzog A; Wong HK
BMC Cancer; 2021 May; 21(1):492. PubMed ID: 33941102
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of hypoxia-inducible factor 1 alpha impacts FoxP3 levels in mycosis fungoides--cutaneous T-cell lymphoma: clinical implications.
Alcántara-Hernández M; Torres-Zárate C; Pérez-Montesinos G; Jurado-Santacruz F; Domínguez-Gómez MA; Peniche-Castellanos A; Ferat-Osorio E; Neri N; Nambo MJ; Alvarado-Cabrero I; Moreno-Lafont M; Huerta-Yepez S; Bonifaz LC
Int J Cancer; 2014 May; 134(9):2136-45. PubMed ID: 24127318
[TBL] [Abstract][Full Text] [Related]
4. TOX acts an oncological role in mycosis fungoides.
Yu X; Luo Y; Liu J; Liu Y; Sun Q
PLoS One; 2015; 10(3):e0117479. PubMed ID: 25811617
[TBL] [Abstract][Full Text] [Related]
5. TOX expression and role in CTCL.
McGirt LY; Degesys CA; Johnson VE; Zic JA; Zwerner JP; Eischen CM
J Eur Acad Dermatol Venereol; 2016 Sep; 30(9):1497-502. PubMed ID: 27345620
[TBL] [Abstract][Full Text] [Related]
6. The Value of Immunohistochemical Expression of TOX, ICOS, and GATA-3 in the Diagnosis of Mycosis Fungoides.
Atwa HA; Abdelrahman DI
Appl Immunohistochem Mol Morphol; 2023 Mar; 31(3):163-171. PubMed ID: 36805367
[TBL] [Abstract][Full Text] [Related]
7. Thymocyte selection-associated high-mobility group box as a potential diagnostic marker differentiating hypopigmented mycosis fungoides from early vitiligo: A pilot study.
Ibrahim MA; Mohamed A; Soltan MY
Indian J Dermatol Venereol Leprol; 2021; 87(6):819-825. PubMed ID: 31857520
[TBL] [Abstract][Full Text] [Related]
8. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
9. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
10. Defining early mycosis fungoides: validation of a diagnostic algorithm proposed by the International Society for Cutaneous Lymphomas.
Vandergriff T; Nezafati KA; Susa J; Karai L; Sanguinetti A; Hynan LS; Ambruzs JM; Oliver DH; Pandya AG
J Cutan Pathol; 2015 May; 42(5):318-28. PubMed ID: 25721994
[TBL] [Abstract][Full Text] [Related]
11. Quantitation of intraepidermal T-cell subsets in formalin-fixed, paraffin-embedded tissue helps in the diagnosis of mycosis fungoides.
Nuckols JD; Shea CR; Horenstein MG; Burchette JL; Prieto VG
J Cutan Pathol; 1999 Apr; 26(4):169-75. PubMed ID: 10335893
[TBL] [Abstract][Full Text] [Related]
12. Eosinophils in mycosis fungoides: an uncommon finding in the patch and plaque stages.
Dalton SR; Chandler WM; Abuzeid M; Hossler EW; Ferringer T; Elston DM; LeBoit PE
Am J Dermatopathol; 2012 Aug; 34(6):586-91. PubMed ID: 22814317
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Validation of Anti-TOX Antibody for Early-Stage Mycosis Fungoides Through Digital Analysis of Tissue Samples.
Pinilla-Pagnon I; Rojo-López R; Coll-Orduña I; Nogales-Moro A; Chao-Crecente M
Am J Dermatopathol; 2024 Apr; 46(4):204-211. PubMed ID: 38457684
[TBL] [Abstract][Full Text] [Related]
14. TOX, TWIST1, STAT4, and SATB1 protein expressions in early-stage mycosis fungoides.
Örnek S; Ozekinci S; Ipin T; Kocaturk E
J Cutan Pathol; 2024 Mar; 51(3):232-238. PubMed ID: 37932931
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical Expression Patterns of CD45RO, p105/p50, JAK3, TOX, and IL-17 in Early-Stage Mycosis Fungoides.
Aladily TN; Abushunar T; Alhesa A; Alrawi R; Almaani N; Abdaljaleel M
Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054387
[TBL] [Abstract][Full Text] [Related]
16. Mycosis fungoides with spongiosis: A potential diagnostic pitfall.
Shamim H; Johnson EF; Gibson LE; Comfere N
J Cutan Pathol; 2019 Sep; 46(9):645-652. PubMed ID: 30989664
[TBL] [Abstract][Full Text] [Related]
17. TOX expression in cutaneous T-cell lymphomas: an adjunctive diagnostic marker that is not tumour specific and not restricted to the CD4(+) CD8(-) phenotype.
Schrader AM; Jansen PM; Willemze R
Br J Dermatol; 2016 Aug; 175(2):382-6. PubMed ID: 26931394
[TBL] [Abstract][Full Text] [Related]
18. [Clinical heterogeneity of poikilodermatous mycosis fungoides: A retrospective study of 12 cases].
Rohmer E; Mitcov M; Cribier B; Lipsker D; Lenormand C
Ann Dermatol Venereol; 2020; 147(6-7):418-428. PubMed ID: 32229035
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in 105 Japanese cases of mycosis fungoides and Sézary syndrome: clusterin expression as a novel prognostic factor.
Tobisawa S; Honma M; Ishida-Yamamoto A; Saijo Y; Iizuka H
J Dermatol Sci; 2013 Sep; 71(3):160-6. PubMed ID: 23702390
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of T-cell antigen losses in mycosis fungoides and CD30-positive cutaneous T-cell lymphoproliferations in a series of 153 patients.
Wechsler J; Ingen-Housz-Oro S; Deschamps L; Brunet-Possenti F; Deschamps J; Delfau MH; Calderaro J; Ortonne N
Pathology; 2022 Oct; 54(6):729-737. PubMed ID: 35577607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
